Patritumab

Drug Profile

Patritumab

Alternative Names: AMG-888; U3-1287

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Amgen; U3 Pharma
  • Developer Daiichi Sankyo Company
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Head and neck cancer
  • Phase I Solid tumours

Most Recent Events

  • 31 Dec 2016 Daiichi Sankyo completes a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (JapicCTI152841)
  • 18 Jul 2016 Biomarkers information updated
  • 01 Jun 2016 Daiichi Sankyo completes phase-I clinical trials in Head and neck cancer (Combination therapy, Metastatic disease) in United Kingdom (IV) (NCT02350712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top